acquisition · Acquired
Acquisition of controlling stake in Yapan Bio
- Expected benefit
- Strengthened biologics capabilities and platform
Q2 FY27 · NSE: PPLPHARMA
Results filed 28 October 2026 · Market cap ₹31,807 crore
Piramal Pharma reported Q2FY27 consolidated revenue of Rs 2,617 Cr, representing 28% YoY growth, with EBITDA increasing 72% YoY to Rs 385 Cr and PAT turning marginally positive to Rs 5 Cr. Topline acceleration was led by the CDMO division (+36% YoY) with robust demand in ADC and on-patent manufacturing, alongside 32% YoY growth in Complex Hospital Generics aided by the Kenalog integration. Reflecting first-half performance, management upgraded its FY27 revenue growth guidance to 19%-20% with expected margin expansion, while preparing for the December 2026 expiry of the Bayer distribution agreement.
| Q2 FY27 | Q1 FY27 | vs previous quarter | Q2 FY26 | vs a year ago | |
|---|---|---|---|---|---|
| Revenue | 2,617 | 2,270 | +15.3% | 2,044 | +28.1% |
| Operating profit (EBIT) | 116 | −28.35 | n.m. | −44.15 | n.m. |
| Operating margin | 4.4% | -1.2% | +567 bps | -2.2% | +658 bps |
| Other income | 35.93 | 89.41 | −59.8% | 65.6 | −45.2% |
| Exceptional items | 0 | 0 | – | 0 | – |
| Profit before exceptional items and tax | 63.89 | −27.02 | n.m. | −60.97 | n.m. |
| Profit to shareholders | 5.58 | −69.39 | n.m. | −99.22 | n.m. |
| Share of joint ventures' and associates' profit | 17.74 | 19.56 | −9.3% | 14.79 | +19.9% |
| Earnings per share (₹) | 0.04 | -0.52 | n.m. | -0.75 | n.m. |
Source: Piramal Pharma Limited’s filing to NSE, 27 October 2026. Operating profit is revenue less every expense except interest, so it leaves out other income and exceptional items. n.m.: not meaningful, because the earlier figure was zero or negative, or the latest one is a loss.
These notes are from the presentation and press release. The concall transcript isn’t filed yet; the notes are rewritten when it is.
| Metric | Guidance | Period |
|---|---|---|
Consolidated Revenue GrowthSourcePress Release, page 2: 'Upgrade FY27 Outlook: Based on the strong first-half performance and continued business momentum, we upgrade our FY27 outlook and now expect revenue growth of 19% to 20%' | 19% to 20% YoY | FY27 |
Consolidated ProfitabilitySourceInvestor Presentation, page 9: 'anticipate 19-20% revenue growth with meaningfully higher profitability.' | Meaningfully higher profitability | FY27 |
Bayer Distribution Expiry ImpactSourceInvestor Presentation, page 18: 'Expected impact on FY27 revenue is low at less than 2%... Improvement in PPL Consolidated EBITDA margin excluding this Bayer Sales & Distribution revenue 50bps' | Less than 2% impact on FY27 revenue; ~50 bps improvement in Consolidated EBITDA margin excluding this revenue | FY27 |
FY27 outlook was upgraded to 19%-20% revenue growth accompanied by meaningfully higher profitability, raised from earlier baseline guidance.
acquisition · Acquired
capacity expansion · On track; new microbiology laboratory commissioned
acquisition · Contributed to Q2FY27 revenues
new product · Launched
Not yet: there’s no transcript.
Management's narrative highlights strong execution, operating leverage, and accelerating demand resulting in an upgraded 19-20% FY27 growth guidance. The reported revenue figures (+28% YoY) and EBITDA growth (+72% YoY) corroborate this operational momentum, with EBITDA margins expanding over 350 bps to 14.7% (company presentation) / 13.3% (excluding other income). However, the narrative omits commentary on balance sheet gearing, where net debt increased by Rs 695 Cr during the half year to Rs 4,859 Cr, and H1FY27 cumulative net profit remained negative at -Rs 64 Cr.
Notes written by gemini-3.8-flash from the documents above on 15 November 2026. They summarise what the company said and can contain mistakes: check the source passage before relying on a point. Not investment advice.